GW Pharmaceuticals to Present at the Cowen 40th Annual Healthcare Conference
February 24, 2020 07:00 ET
|
GW Pharmaceuticals plc
LONDON and CARLSBAD, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization...
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Fourth Quarter and Year Ending December 31, 2019 and Host Conference Call on February 25th, 2020
February 12, 2020 08:11 ET
|
GW Pharmaceuticals plc
LONDON and CARLSBAD, Calif., Feb. 12, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and...
GW Pharmaceuticals and Greenwich Biosciences Submit Supplemental New Drug Application to U.S. FDA for Epidiolex® (cannabidiol) for the Treatment of Tuberous Sclerosis Complex
February 03, 2020 07:00 ET
|
GW Pharmaceuticals plc
LONDON and CARLSBAD, Calif., Feb. 03, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and...
GW Pharmaceuticals Pre-Announces Preliminary Unaudited Fourth Quarter and Full-Year 2019 Net Product Sales
January 12, 2020 18:00 ET
|
GW Pharmaceuticals plc
- Total preliminary net product sales of approximately $108 million for the fourth quarter and approximately $309 million for the full year - - Total Epidiolex® preliminary net product sales of...
GW Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 07, 2020 13:13 ET
|
GW Pharmaceuticals plc
LONDON and CARLSBAD, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and...
Greenwich Biosciences, a GW Pharmaceuticals Company, Presents New Data for EPIDIOLEX® (cannabidiol) in Patients with Tuberous Sclerosis Complex (TSC) at the American Epilepsy Society Annual Meeting
December 07, 2019 12:00 ET
|
GW Pharmaceuticals plc
CARLSBAD, Calif., Dec. 07, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines,...
GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting
December 05, 2019 07:00 ET
|
GW Pharmaceuticals plc
LONDON and CARLSBAD, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription...
GW Pharmaceuticals to Present at Upcoming Investor Conferences
November 22, 2019 07:00 ET
|
GW Pharmaceuticals plc
CARLSBAD, Calif., Nov. 22, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the...
GW Pharmaceuticals receives positive NICE recommendation for EPIDYOLEX® (cannabidiol) oral solution for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy
November 10, 2019 19:01 ET
|
GW Pharmaceuticals plc
GW also welcomes the positive guideline recommendation for Sativex® (nabiximols) for the treatment of spasticity due to multiple sclerosis as part of NICE’s evaluation of cannabis-based medicinal...
GW Pharmaceuticals receives positive NICE recommendation for EPIDYOLEX® (cannabidiol) oral solution for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy
November 10, 2019 19:01 ET
|
GW Pharmaceuticals plc
GW also welcomes the positive guideline recommendation for Sativex® (nabiximols) for the treatment of spasticity due to multiple sclerosis as part of NICE’s evaluation of cannabis-based medicinal...